+1 201 316 9200
+81 (0)3 6264 0600
Europe & Rest of World
+41 61 316 81 11
Lonza’s Epibase™ In Silico platform is a patented T cell epitope screening tool for the identification of potential epitopes in protein-based vaccine targets. The tool is driven by sequence information, structural bioinformatics, and experimental data. The Epibase™ In Silico tool predicts potential peptide/HLA binding, and HLA Class I CD8+ and CD4+ T cell epitopes. In order to provide the optimal number of antigens that confer the broadest protection against infection, Epibase™ In Silico can identify conserved regions across several virus strains in order to help design vaccines for maximum coverage.
The Epibase™ In Silico tool supports lead candidate selection, ranking, optimization, and rational design for the development of efficacious vaccines.
Help Increase Chance of Clinical Success
Save Time and Money in Development